| Name | Value |
|---|---|
| Revenues | 181.1M |
| Cost of Revenue | 40.9M |
| Gross Profit | 140.2M |
| Operating Expense | 131.7M |
| Operating I/L | 8.5M |
| Other Income/Expense | -10.4M |
| Interest Income | 5.0M |
| Pretax | -1.9M |
| Income Tax Expense | 2.9M |
| Net Income/Loss | -4.8M |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions in the United States. The company's flagship products include EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used for targeted nerve treatment. Additionally, Pacira BioSciences develops proprietary multivesicular liposome drug delivery technology, encapsulating drugs without altering their molecular structure.